Phase 3 RCT in 3900 cisgender men and transgender people without HIV: a mosaic Ad26.Mos4.HIV plus gp140 vaccine regimen vs placebo did not prevent HIV-1 (incidence 3.63 vs 3.35 per 100 person-years; efficacy -0.7%, p=0.97).
RCTn = 3,900
Buchbinder et al. Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial